The kinetics of blood brain barrier permeability and targeted doxorubicin delivery into brain induced by focused ultrasound.

Focused ultrasound (FUS) combined with a circulating microbubble agent is a promising strategy to non-invasively disrupt the blood-brain barrier (BBB) and could enable targeted delivery of therapeutics that normally do not leave the brain vasculature. This study investigated the kinetics of the BBB permeability using dynamic contrast-enhanced MRI (DCE-MRI) and the resulting payload of the chemotherapy agent, doxorubicin (DOX). We also investigated how the disruption and drug delivery were affected by a double sonication (DS) with two different time intervals (10 or 120 min). Two locations were sonicated transcranially in one hemisphere of the brain in 20 rats using a 690 kHz FUS transducer; the other hemisphere served as a control. For BBB disruption, 10 ms bursts were applied at 1 Hz for 60s and combined with IV injection of a microbubble ultrasound contrast agent (Definity; 10 μl/kg). DOX was injected immediately after the second location was sonicated. The transfer coefficient (K(trans)) for an MRI contrast agent (Gd-DTPA) was estimated serially at 4-5 time points ranging from 30 min to 7.5 hrs after sonication using DCE-MRI. After a single sonication (SS), the mean K(trans) was 0.0142 ± 0.006 min(-1) at 30 min and was two or more orders of magnitude higher than the non-sonicated targets. It decreased exponentially as a function of time with an estimated half-life of 2.22 hrs (95% confidence intervals (CI): 1.06-3.39 hrs). Adding a second sonication increased K(trans), and with a 120 min interval between sonications, prolonged the duration of the BBB disruption. Mean K(trans) estimates of 0.0205 (CI: 0.016-0.025) and 0.0216 (CI: 0.013-0.030) min(-1) were achieved after DS with 10 and 120 min delays, respectively. The half-life of the K(trans) decay that occurred as the barrier was restored was 1.8 hrs (CI: 1.20-2.41 hrs) for a 10 min interval between sonications and increased to 3.34 hrs (CI: 0.84-5.84 hrs) for a 120 min interval. DOX concentrations were significantly greater than in the non-sonicated brain for all experimental groups (p<0.0001), and 1.5-fold higher for DS with a 10 min interval between sonications. A linear correlation was found between the DOX concentration achieved and the K(trans) measured at 30 min after sonication (R: 0.7). These data suggest that one may be able to use Gd-DTPA as a surrogate tracer to estimate DOX delivery to the brain after FUS-induced BBB disruption. The results of this study provide information needed to take into account the dynamics BBB disruption over time after FUS.

[1]  Natalia Vykhodtseva,et al.  Progress and problems in the application of focused ultrasound for blood-brain barrier disruption. , 2008, Ultrasonics.

[2]  Feng-Yi Yang,et al.  Focused ultrasound and interleukin-4 receptor-targeted liposomal doxorubicin for enhanced targeted drug delivery and antitumor effect in glioblastoma multiforme. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[3]  K. Hynynen,et al.  Influence of exposure time and pressure amplitude on blood-brain-barrier opening using transcranial ultrasound exposures. , 2010, ACS chemical neuroscience.

[4]  Kullervo Hynynen,et al.  Ultrasound insertion loss of rat parietal bone appears to be proportional to animal mass at submegahertz frequencies. , 2011, Ultrasound in medicine & biology.

[5]  Yao-Sheng Tung,et al.  Microbubble-Size Dependence of Focused Ultrasound-Induced Blood–Brain Barrier Opening in Mice In Vivo , 2010, IEEE Transactions on Biomedical Engineering.

[6]  Natalia Vykhodtseva,et al.  MRI-guided targeted blood-brain barrier disruption with focused ultrasound: histological findings in rabbits. , 2005, Ultrasound in medicine & biology.

[7]  K. Hynynen,et al.  Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. , 2001, Radiology.

[8]  K. Hynynen,et al.  Effects of acoustic parameters and ultrasound contrast agent dose on focused-ultrasound induced blood-brain barrier disruption. , 2008, Ultrasound in medicine & biology.

[9]  R. Brasch,et al.  Effect of varying the molecular weight of the MR contrast agent Gd‐DTPA‐polylysine on blood pharmacokinetics and enhancement patterns , 1994, Journal of magnetic resonance imaging : JMRI.

[10]  A. Moore,et al.  Tissue distribution and disposition of daunomycin (NCS-82151) in mice: fluorometric and isotopic methods. , 1970, Cancer chemotherapy reports.

[11]  K. Hynynen,et al.  Blood-brain barrier disruption induced by focused ultrasound and circulating preformed microbubbles appears to be characterized by the mechanical index. , 2008, Ultrasound in medicine & biology.

[12]  A. Di Marco,et al.  Adriamycin (NSC-123,127): a new antibiotic with antitumor activity. , 1969, Cancer chemotherapy reports.

[13]  Natalia Vykhodtseva,et al.  Focal disruption of the blood-brain barrier due to 260-kHz ultrasound bursts: a method for molecular imaging and targeted drug delivery. , 2006, Journal of neurosurgery.

[14]  Feng-Yi Yang,et al.  Reversible blood-brain barrier disruption by repeated transcranial focused ultrasound allows enhanced extravasation. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[15]  Kit S Lam,et al.  PEG-oligocholic acid telodendrimer micelles for the targeted delivery of doxorubicin to B-cell lymphoma. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[16]  John A Butman,et al.  Real-time image-guided direct convective perfusion of intrinsic brainstem lesions. Technical note. , 2007, Journal of neurosurgery.

[17]  J. Holland,et al.  Therapeutic effect and toxicity of adriamycin in patients with neoplastic disease , 1971, Cancer.

[18]  木下 学 Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption , 2007 .

[19]  Xin-guo Jiang,et al.  TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[20]  C. McArdle,et al.  Studies on the in vivo disposition of adriamycin in human tumours which exhibit different responses to the drug. , 1986, British Journal of Cancer.

[21]  Natalia Vykhodtseva,et al.  Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI‐guided focused ultrasound , 2007, International journal of cancer.

[22]  Win-Li Lin,et al.  Quantitative evaluation of focused ultrasound with a contrast agent on blood-brain barrier disruption. , 2007, Ultrasound in medicine & biology.

[23]  V. P. Collins,et al.  Uptake of Adriamycin in tumour and surrounding brain tissue in patients with malignant gliomas , 1990, Acta Neurochirurgica.

[24]  K. Hynynen,et al.  Multiphoton Imaging of Ultrasound/Optison Mediated Cerebrovascular Effects in vivo , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[25]  Kullervo Hynynen,et al.  Brain arterioles show more active vesicular transport of blood-borne tracer molecules than capillaries and venules after focused ultrasound-evoked opening of the blood-brain barrier. , 2006, Ultrasound in medicine & biology.

[26]  A. Jackson,et al.  Improved 3D quantitative mapping of blood volume and endothelial permeability in brain tumors , 2000, Journal of magnetic resonance imaging : JMRI.

[27]  P. Tofts,et al.  Measurement of the blood‐brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts , 1991, Magnetic resonance in medicine.

[28]  K. Hynynen,et al.  Cellular mechanisms of the blood-brain barrier opening induced by ultrasound in presence of microbubbles. , 2004, Ultrasound in medicine & biology.

[29]  E. Konofagou,et al.  Permeability assessment of the focused ultrasound-induced blood–brain barrier opening using dynamic contrast-enhanced MRI , 2010, Physics in medicine and biology.

[30]  J. Roh,et al.  Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. , 1986, Cancer research.

[31]  Kullervo Hynynen,et al.  Effect of focused ultrasound applied with an ultrasound contrast agent on the tight junctional integrity of the brain microvascular endothelium. , 2008, Ultrasound in medicine & biology.

[32]  Miss A.O. Penney (b) , 1974, The New Yale Book of Quotations.

[33]  E. Konofagou,et al.  Permeability dependence study of the focused ultrasound‐induced blood–brain barrier opening at distinct pressures and microbubble diameters using DCE‐MRI , 2011, Magnetic resonance in medicine.

[34]  D M Shames,et al.  Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. , 1998, AJR. American journal of roentgenology.

[35]  Ferenc A. Jolesz,et al.  Local and reversible blood–brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications , 2005, NeuroImage.

[36]  K. Hynynen,et al.  Targeted disruption of the blood–brain barrier with focused ultrasound: association with cavitation activity , 2006, Physics in medicine and biology.

[37]  G. Bonadonna,et al.  Phase I and preliminary phase II evaluation of adriamycin (NSC 123127). , 1970, Cancer research.

[38]  G. Bonadonna,et al.  Clinical Trials with Adriamycin in Leukemia and Solid Tumors , 1969, Tumori.

[39]  K. Hynynen,et al.  Ultrasound Enhanced Delivery of Molecular Imaging and Therapeutic Agents in Alzheimer's Disease Mouse Models , 2008, PloS one.

[40]  E. Frei,et al.  Clinical trials with adriamycin , 1971, Cancer.

[41]  G J Murray,et al.  Image-guided, direct convective delivery of glucocerebrosidase for neuronopathic Gaucher disease , 2007, Neurology.

[42]  Yuan Cheng,et al.  Experimental Study on Targeted Methotrexate Delivery to the Rabbit Brain via Magnetic Resonance Imaging–Guided Focused Ultrasound , 2009, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[43]  K. Hynynen,et al.  The impact of standing wave effects on transcranial focused ultrasound disruption of the blood–brain barrier in a rat model , 2010, Physics in medicine and biology.

[44]  Mu-Yi Hua,et al.  Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment. , 2010, Radiology.

[45]  Rajiv Chopra,et al.  Antibodies Targeted to the Brain with Image-Guided Focused Ultrasound Reduces Amyloid-β Plaque Load in the TgCRND8 Mouse Model of Alzheimer's Disease , 2010, PloS one.

[46]  A. Stan,et al.  Doxorubicin-induced cell death in highly invasive human gliomas. , 1999, Anticancer research.

[47]  K. Hynynen,et al.  Targeted delivery of antibodies through the blood-brain barrier by MRI-guided focused ultrasound. , 2006, Biochemical and biophysical research communications.

[48]  Win-Li Lin,et al.  Quantitative evaluation of the use of microbubbles with transcranial focused ultrasound on blood-brain-barrier disruption. , 2008, Ultrasonics sonochemistry.

[49]  L. Bakay,et al.  Ultrasonically produced changes in the blood-brain barrier. , 1956, A.M.A. archives of neurology and psychiatry.